ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Hepatitis and rheumatoid arthritis (RA)"

  • Abstract Number: 472 • 2017 ACR/ARHP Annual Meeting

    Viral Hepatitis Influences Patient Reported Outcomes Measures in Rheumatoid Arthritis

    Suraj Timilsina1, Harlan Sayles2, Bryant R. England3, James R. O'Dell4, Ted R. Mikuls5 and Kaleb Michaud2, 1Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, 4Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 5Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Viral hepatitis may complicate the treatment of RA since select DMARD have the potential to cause hepatotoxicity or reactivation of latent viral infections. Whether…
  • Abstract Number: 432 • 2016 ACR/ARHP Annual Meeting

    Monitoring Hepatitis B Screening Compliance in Patients with Rheumatoid Arthritis (RA) Receiving Anti-TNF Therapy

    Vedashree Panthulu1 and John Waterman2, 1Rheumatology, University of Connecticut Health Center, Farmington, CT, 2Rheumatology, Connecticut VA Healthcare System, Newington, CT

    Background/Purpose:   The risk of infection in patients with RA is higher than in comparable patients but still the vaccination rates in RA patients are low. …
  • Abstract Number: 1521 • 2016 ACR/ARHP Annual Meeting

    Disease Characteristics and Change of Arthritis Activity According to Treatment in Hepatitis B Surface Antigen Positive Rheumatoid Arthritis Patients

    Yeonghee Eun1, Hyemin Jeong1, Eun-Jung Park2, Ji Young Chai3, Hyungjin Kim1, Jaejoon Lee1, Eun-Mi Koh1 and Hoon-Suk Cha4, 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Department of Medicine, Division of Rheumatology, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Jeju, South Korea, 3Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of, 4Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose:  Rheumatoid arthritis (RA) treatment may differ according to hepatitis B state and consequently bring about different outcome of arthritis. Only a small number of…
  • Abstract Number: 2655 • 2016 ACR/ARHP Annual Meeting

    Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs

    Toshiyuki Watanabe1, Shinji Fukaya2 and Kazumasa Akikawa2, 13rd Department of Internal Medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan, 23rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan

    Background/Purpose:  Reactivation of hepatitis B virus (HBV) is one of the most serious complications in rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs…
  • Abstract Number: 1365 • 2013 ACR/ARHP Annual Meeting

    Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics

    Jun Nakamura1, Takao Nagashima1, Katsuya Nagatani2, Taku Yoshio3, Masahiro Iwamoto4 and Seiji Minota5, 1Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, 2Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, 3Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, 4Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Tochigi, Japan, 5The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan

    Background/Purpose: Reactivation of hepatitis B virus (HBV) is very problematic in patients who are receiving biologics. Optimal precaution and management for those patients are still…
  • Abstract Number: 378 • 2013 ACR/ARHP Annual Meeting

    HBV Reactivation and Consequent Hepatitis In Rheumatoid Arthritis Patients With Different HBV Carring State: A Clinical Observation Follow-Up

    Lie Dai, An Qi Liang, Ying Qian Mo, Jian Da Ma, Le Feng Chen, Dong Hui Zheng and Lang Jing Zhu, Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

    Background/Purpose: Approximate 7.2% Chinese were infected with hepatitis B virus (HBV), and the prevalence of concurrent HBV carriers in Chinese rheumatoid arthritis (RA) patients was…
  • Abstract Number: 175 • 2012 ACR/ARHP Annual Meeting

    The Impact of Hepatitis Screening On Diagnosis and Treatment in Rheumatoid Arthritis

    Richard Conway1, Michele Doran2, Finbar (Barry) D. O'Shea3 and Gaye Cunnane2, 1Rheumatology, St James's Hospital, Dublin, Ireland, 2Dept of Rheumatology, St James's Hospital, Dublin, Ireland, 3Rheumatology Dept, St James's Hospital, Dublin, Ireland

    Background/Purpose: Hepatitis testing is an important pre-requisite to the diagnosis and treatment of patients with rheumatic disease. Joint symptoms may be a manifestation of acute…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology